COAG
Hemab Therapeutics Holdings, Inc. Common Stock • NASDAQ
$28.50 ▲ 1.79% (+0.50)
COAG
Hemab Therapeutics Holdings, Inc. Common StockNASDAQ • $28.50 ▲ 1.79% (+0.50)
Market Cap $57.25 M
52w High $36.61
52w Low $23.00
P/E -2.81
Volume 123.66K
Outstanding Shares 2.01M
Market Cap $57.25 M
52w High $36.61
52w Low $23.00
P/E -2.81
Volume 123.66K
Outstanding Shares 2.01M
About Hemab Therapeutics Holdings, Inc. Common Stock
https://www.hemab.comHemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.
CEO
Benny Sorensen
Compensation Summary
(Year )
Total Compensation (Unknown At The Moment)
Industry Biotechnology
Sector Healthcare
Went public May 1, 2026
Method of going public IPO
Full time employees 59
AUG
20 THU
Upcoming Earnings
Date Aug 20, 2026
Day Thursday
Revenue Est. —
ETFs Holding This Stock
Summary
Total 1
Showing Top 1 of 1
Price Target
Target High $50
Target Low $36
Target Median $40.5
Target Consensus $41.75